PrimeRFP SCOUT · Federal Contract Recompete Brief

15B50926F00000053Fy26 pharmacy TAKEDA jan-sept — Takeda Pharmaceuticals America, Inc

Takeda Pharmaceuticals America, Inc holds $6.5M across 96 federal awards, concentrated at Department of Justice (DOJ). This PIID sits alongside 4 related awards under parent V797D50492. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Feb 28, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Fmc Fort Worth

Awarding office

Takeda Pharmaceuticals America, Inc

Recipient

Feb 28, 2026

PoP end

$205K

Obligated

$205K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Takeda Pharmaceuticals America, Inc — $90

Contract facts

Federal

Contract number15B50926F00000053

Also listed asV797D50492-15B50926F00000053

AgencyFmc Fort Worth

Awarding officeFmc Fort Worth

Awarding agencyDepartment of Justice (DOJ)

Funding agencyDepartment of Justice (DOJ)

IncumbentTakeda Pharmaceuticals America, Inc

CAGE4DE70

UEIDDEVYUAXJ624

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVV797D50492

Place of performanceLEXINGTON MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 28, 2026

PoP end (current)Feb 28, 2026

Obligated$205K

Current value$205K

Potential value$205K

FY26 PHARMACY TAKEDA JAN-SEPT is a federal award for Fmc Fort Worth held by Takeda Pharmaceuticals America, Inc. Estimated value $205K ($205K obligated). Current period of performance ends Feb 28, 2026. Last award drew 1 bidder. Place of performance: LEXINGTON MA.

Recompete timing

Public

● Past PoP end (174 days ago)

Current PoP ended Feb 28, 2026 (174 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Takeda Pharmaceuticals America, Inc — $6.5M obligated across 96 awards (firm-wide, all agencies) · lead buyer Department of Justice (DOJ).

% of firm-wide obligated ($6.5M) · all agencies

Department of Justice (DOJ)$4.0M · 62%Department of Veterans Affairs (VA)$2.5M · 38%Department of Defense (DOD)$20K · 0%

Open full company profile →

Related awards

Same parent · incumbent

15B50926F00000076

FY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER

$549K

Sep 30, 2026

15B50926F00000018

FY26 TAKEDA OCT-NOV

$320K

Sep 30, 2026

36C26026P0420

GAMMAGARD LIQUID ERC - GLOBULIN,IMMUNE (IV) 10% INJ

$108K

Sep 30, 2026

36C26026F0130

ADZYNMA 1500IU INJ,LYPHL.

$179K

Jan 3, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 15B50926F00000053?

15B50926F00000053 (Fy26 pharmacy TAKEDA jan-sept) is a Fmc Fort Worth award with a potential value of $205K, currently held by Takeda Pharmaceuticals America, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 15B50926F00000053?

Fmc Fort Worth awarded 15B50926F00000053 to Takeda Pharmaceuticals America, Inc (potential $205K).

Who is the incumbent on 15B50926F00000053?

Takeda Pharmaceuticals America, Inc is the incumbent with $6.5M across 96 related awards in SCOUT’s public footprint. The current period of performance ends Feb 28, 2026.

When does Takeda Pharmaceuticals America, Inc’s 15B50926F00000053 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 28, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Feb 11, 2026